HitGen Enters Drug Discovery Collaboration with Scripps Research Institute

HitGen of Chengdu announced its fourth collaboration in three months: it will work with The Scripps Research Institute (TSRI) and its affiliate, the California Institute for Biomedical Research (Calibr), to discover and develop new small molecule drug candidates. Initially, the collaboration will target unmet needs in oncology, regenerative medicine and virology. Since February, HitGen has announced collaborations with Cancer Research UK, Merck/MSD and Pfizer. The technology behind HitGen's DNA encoded libraries was originally conceived at TSRI. More details... Stock Symbols: (NYSE: MRK) (NYSE: PFE) Share this with colleagues: // //